WHO has released a statement confirming that it has accepted Solidarity Trial’s International Steering Committee’s recommendation to halt the trial’s hydroxychloroquine and lopinavir/ritonavir arms.
WHO established the Solidarity Trial to find an effective COVID-19 treatment for patients in critical conditions/hospitalized.
This recommendation came in light of the evidence for hydroxychloroquine vs standard-of-care as well as for lopinavir/ritonavir vs standard-of-care – from this review, the trial results produce little to no reduction in the mortality of COVID-19 patients who have been hospitalized as compared to the standard of care.
WHO also confirms that the ‘decision applies only to the conduct of the Solidarity trial in hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patients or as pre- or post-exposure prophylaxis for COVID-19’
Source: WHO[Media Release]
